2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2931 Suzetrigine for sickle cell disease pain: A retrospective study with patient reported outcomes

Joseph Brennan deBettencourt, MD, Julia Ruelle2, Christine Greco, MD3, Carolina Donado Rincon, MD4, Charles Berde, MD, PhD5, Natasha M. Archer, MD, MPH6
1 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
2 Harvard Medical School, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States
6 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States

Introduction: Pain is the leading cause of hospitalization among adolescents with Sickle Cell Disease (SCD), and management remains heavily opioid-dependent, contributing to high cumulative opioid exposure as well as side-effects and complications from opioid use. Non-opioid and opioid-sparing alternatives remain a priority for the field of SCD pain management. Suzetrigine, a selective Nav1.8 sodium channel inhibitor, was recently introduced into clinical practice for acute pain, acting peripherally to block nociceptive signal transmission. Nav1.8-related pathways have been implicated in sickle pain in murine models. Little is known about suzetrigine’s optimal use and effect on hospitalization characteristics or patient-reported outcomes in this population.

Methods: We performed a retrospective analysis including patient-reported outcomes of suzetrigine use from December 2025 through July of 2026 in individuals with SCD ≥16 years admitted for a pain episode. Chart review confirmed SCD diagnosis and inpatient suzetrigine administration. Data abstracted included patient demographics, pain numerical rating scale (NRS), inpatient medication use (days on IV opioids, morphine milligram equivalents per day), complications, discharge medications, and follow-up/readmissions within 30 days. A convenience sample of patients with follow-up visits or admissions during the study period were approached for a patient-reported outcomes survey and consented if interested. Data were entered into REDCap; descriptive statistics were performed in R (RStudio, Posit Software, PBC, v2026.06.0+242).

Results: 17 unique patients, the majority with HbSS genotype (13/17, 76%), used suzetrigine during 44 inpatient encounters. The mean age at first admission was 18 years (range 16-22 years), 9 were male (53%), 7 were female (41%) and one non-binary (6%). 4 (24%) patients had a chronic pain diagnosis and were on more baseline pain medications prior to initial admission than those without. The majority of patients (14/17, 82%) started suzetrigine within the first 48 hours and the majority (12/17, 68%) continued the medication as an outpatient script. Average days on IV opioids and length of stay were 5.4 (SD 4.8) and 6.7 (SD 4.9) days, respectively. NRS scores had a mean change of -0.79 (SD 2.09) from before suzetrigine administration to 24 hours after. 11 patients (69%) had more than one admission for pain during the 8-month study period, suggestive of a more severe pain phenotype. 6 of those patients received suzetrigine during more than one admission, and 5 patients had subsequent admissions without suzetrigine. Among the 6 repeat users, LOS trends were mixed relative to their prior year (2 increased, 4 decreased) and change was not statistically significant, consistent with the small sample size. 2 patients had outpatient suzetrigine prescriptions denied by insurance, limiting repeat use. 

6 of 17 (29%) of participants completed the survey and overall opinion skewed towards positive (4 out of 6 on a Likert scale, SD 0.8). While some patients found it beneficial and reported no side effects attributable to suzetrigine (3/5), some felt it was not helpful for their pain and associated with side effects such as nausea and fatigue. Qualitative statements from patients further supported this diversity of responses, one patient said it was “[…] a (sic) overall good medicine” while another said, “I do not think suzetrigine helped my pain but it is difficult to truly be sure of that, considering it was being used alongside many other pain meds”. 

Conclusion: The repeat use of suzetrigine in 35% of participants and encouraging responses from patient surveys suggest that some patients and providers see suzetrigine as beneficial for managing SCD-related pain. It is overall well tolerated in this patient population, however some patients reported side effects (nausea, sedation) commonly associated with opioids, a concomitant medication in the majority (16/17, 94%) of encounters. The response may depend on baseline characteristics, such as age, comorbidities, and concurrent medications.  While this is a limited sampling of patients, the diversity of patient presentations and response to the medication suggests further research should be pursued to understand the optimal use of this novel analgesic.

Natasha M. Archer, MD, MPH: Quilt Health - Current holder of stock options in a privately-held company; CSL Behring - Research Funding; Agios - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony)